Publications

Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008) by Mendes RE, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2010; 36 (4): 374-379

Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp. and Aspergillus spp.: Results from the Global SENTRY Antimicrobial Surveillance Program (2008). by Messer SA, Jones RN, Moet GJ, Kirby JT and Castanheira M published in J. Clin. Microbiol. 2010; 48 (8): 2984-2987

Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. by Putnam SD, Sader HS, Moet GJ, Mendes RE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 67 (4): 359-368

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. by Jones RN, Jacobs MR and Sader HS published in Int. J. Antimicrob. Agents 2010; 36 (3): 197-204

Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). by Castanheira M, Watters AA, Mendes RE, Farrell DJ, Jones RN published in J. Antimicrob. Chemother. 2010; 65 (7): 1353-1358

Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. by Johnson JR, Johnston B, Clabots C, Kushkowski MA and Castanheira M published in Clin. Infect. Dis. 2010; 51 (3): 286-294

Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. by Jones RN published in Clin. Infect. Dis. 2010; 51 (Suppl 1): S81-S87

Escherichia coli resistant to quinolones at a comprehensive cancer center. by Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA and Rolston KV published in Diagn. Microbiol. Infect. Dis. 2010; 67: 266-269

Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. by Sader HS, Farrell DJ and Jones RN published in Int. J. Antimicrob. Agents 2010; 36 (1): 28-32

Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. by Farrell DJ, Sader HS, Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (6): 2735

In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. by Biedenbach DJ, Ross JE, Putnam SD and Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (5): 2273-2275

CEM-101 activity against Gram-positive organisms. by Woosley LN, Castanheira M, Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (5): 2182-2187

CEM-101, a novel fluoroketolide: Antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. by Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 66 (4): 393-401

MIC quality control guidelines and disk diffusion test optimization for CEM-101, a novel fluoroketolide. by Jones RN, Ross JE, Rhomberg PR published in J. Clin. Microbiol. 2010; 48 (4): 1470-1473

Performance of fusidic acid (CEM-102) susceptibility testing reagents: Broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus. by Jones RN, Castanheira M, Rhomberg PR, Woosley LN and Pfaller MA published in J. Clin. Microbiol. 2010; 48: 972-976

Sustained antimicrobial activity of tigeycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States medical centers from 2004 through 2008. by Putnam SD, Sader HS, Farrell DJ and Jones RN published in J. Chemother. 2010; 22 (1): 13-16

Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102). by Biedenbach DJ, Rhomberg PR, Mendes RE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 66 (3): 301-307

Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC in Long Beach, California. by Le J, Castanheira M, Burgess DS, McKee B, Iqbal R, Jones RN published in J. Clin. Microbiol. 2010; 48 (2): 623-625

Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 µg/mL isolated in the United States and European hospitals (2006-2008). by Sader HS, Becker HK, Moet GJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 66 (3): 329-331

Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada by Pfaller MA, Castanheira M, Sader HS, Jones RN published in Int. J. Antimicrob. Agents 2010; 35 (3): 282-287

Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from Phase IV clinical trial for linezolid. by Mendes RE, Sader HS, Deshpande LM, Diep BA, Chamers HF, Jones RN published in J. Clin. Microbiol. 2010; 48 (2): 568-574

Wild-type MIC distributions and epidemiologic cutoff values for the Echinocandins and Candida spp. by Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J and Diekema D published in J. Clin. Microbiol. 2010; 48 (1):52-56

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States by Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley I, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (6): 2716-2719

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species by Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN published in J. Clin. Microbiol. 2010; 48 (5); 1592-1599

Anidulafungin (ANID) Potency Compared to other Antifungal Agents: SENTRY Antimicrobial Surveillance Program Results for 2008 (Worldwide), Lead author: Jones RN, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Activity of Omiganan 1% Gel, a Novel Cationic Peptide in Preventing Catheter Related Infections: Final Results of a Phase 3 Trial, Lead author: Jones RN, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Sustained Activity of Tigecycline Against Methicillin-Resistant S. aureus from United States Medical Centers (2004-2008), Lead author: Sader HS, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Evaluation of Daptomycin Activity Tested against 35,058 Bacterial Strains from Hospitalized Patients: Summary of a 7 Year Surveillance Program for North America (2002-2008), Lead author: Sader HS, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Activity of Telavancin and Comparator Agents Tested against Gram-Positive Isolates Cultured from Skin and Skin Structure Infections, Lead author: Mendes RE, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Contemporary Antimicrobial Activity of CEM-102 (Fusidic Acid) Against Canadian Isolates of Staphylococci and Streptococci (2001-2006), Lead author: Rhomberg PR, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Update on Spectrum of CEM-102 (Fusidic Acid) Against Contemporary Wildtype Bacterial Species Including Mutational Resistance Analysis, and Synergy Testing, Lead author: Rhomberg PR, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Oritavancin Activity tested against Resistant Subsets of Gram-Positive Pathogens, Lead author: Jones RN, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Telavancin Activity Tested Against Gram-Positive Pathogens Responsible for Bloodstream Infections Collected during a Global Surveillance Program (2007-2008), Lead author: Mendes RE, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

CEM-101, A novel fluoroketolide: Activity against recent (2008) isolates of multidrug-resistant S. pneumoniae, Lead author: Jones RN, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Antimicrobial Susceptibility of a Worldwide Collection of Stenotrophomonas maltophilia Tested Against Tigecycline and Agents Used for S. maltophilia Infections, Lead author: Sader HS, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Comprehensive investigations of piperacillin/tazobactam (P/T) generic formulations compared to branded lots: Studies of 46 lots from 29 manufacturers, Lead author: Moet G, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Validity of CLSI Disk Diffusion Zone Correlates for Enterobacteriaceae versus Older cephalosporins, Lead author: Badal, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Pilot studies to guide CLSI re-evaluations of S. pneumoniae and ß-haemolytic streptococcal disk diffusion criteria for commonly used penicillins and cephalosporins, Lead author: Rhomberg PR, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Performance of CEM-102 (Fusidic Acid) Susceptibility Testing Reagents; Broth Microdilution, Disk Diffusion and Etest Methods, Lead author: Rhomberg PR, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

In Vitro Activity of Ceftaroline Tested Against Recent Clinical Isolates from the United States (USA), Lead author: Sader HS, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Bactericidal Activity of Ceftaroline Combined with NXL-104 against Critical Targeted Organisms Possessing Various Resistance Mechanisms, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

In Vitro Antibacterial Spectrum of BC-3205, a Novel Pleuromutilin Derivative for Oral Use in Humans, Lead author: Ivezic-Schoenfeld, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

In Vitro Antibacterial Spectrum of BC-7013, a Novel Pleuromutilin Derivative for Topical Use in Humans, Lead author: Ivezic-Schoenfeld, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of the Novel Cephalosporin CXA-101 Tested in Combination with Tazobactam Against Cephalosporin-resistant Enterobacteriaceae, P. aeruginosa and B. fragilis, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

First Year Antimicrobial Surveillance Results for CEM-101, a Novel Fluoroketolide with Potent Activity Against Pathogens Associated with Community-acquired Bacterial Pneumonia, Lead author: Jones RN, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of CEM-101, a Novel Fluoroketolide, Tested Against Invasive Isolates of N. meningitidis from a Worldwide Collection, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of ACHN-490, a Novel Neoglycoside Antibiotic, against Complicated Urinary Tract Infection Pathogens From the United States and Europe, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Antimicrobial Activity of ACHN-490, a Neoglycoside, Tested Against a Contemporary Collection of Clinical Isolates Including Problematic Antimicrobial-Resistant Phenotypes, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Clinical Outcomes of Infections Caused by Extended-Spectrum &#223-Lactamase (ESBL)-Producing Bacteria with Reduced Carbapenem Susceptibility, Lead author: Le, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Correlation of Baseline Methicillin-Resistant Staphylococcus aureus (MRSA) Isolate Characteristics with Clinical Outcome from a Randomized Phase 4 Clinical Trial of Complicated Skin and Soft Tissue Infections, Lead author: Hogan, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA